FORMULATIONS BASED ON ANTI-CD38 ANTIBODIES FOR SUBCUTANEOUS ADMINISTRATION Russian patent published in 2025 - IPC A61K39/00 A61K39/395 A61K47/10 A61P29/00 A61P35/00 A61P37/06 C07K16/28 

FIELD: biotechnology.

SUBSTANCE: disclosed are formulations for treating a disease characterized by the presence of CD38+ cells, wherein the formulation is suitable for subcutaneous administration and contains 125-155 mg/ml of anti-CD38 antibodies, as well as their use for treating a disease or condition characterized by the presence of CD38⁺ cells, which is a CD38⁺ haematological malignant neoplasm, an autoimmune or inflammatory disease or condition. Also disclosed is a packaged pharmaceutical product for treating a disease characterized by the presence of CD38+ cells, containing a sterile container or device containing a therapeutically effective amount of the formulation, wherein formulation contains 125-155 mg/ml of anti-CD38.

EFFECT: invention can be used to treat malignant neoplasms, autoimmune or inflammatory diseases.

13 cl, 29 dwg, 31 tbl, 7 ex